Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)

  • Technology appraisal
  • TA435
  • Published: 
Download guidance (PDF)

Background

Gilead was invited to submit evidence for this single technology appraisal for tenofovir alafenamide in May 2016.

Gilead has advised NICE that the particular population that would have the greatest need for tenofovir alafenamide cannot be differentiated from the broader population without additional data. Gilead therefore did not make a submission to NICE.

NICE has therefore terminated this single technology appraisal.